Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q3 2021 · 10-Q
Revenue$27.81M$27.81M−81.8% vs Q3 2020 Net Income-$6.98M-$6.98MN/M vs Q3 2020 EPS Diluted-$0.24-$0.24N/M vs Q3 2020 Gross Profit$10,930,000−45.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,070,000N/M Free Cash Flowderived-$11,046,000N/M Margins · derivedGross margin39.3%+26.2 pt vs Q3 2020
Operating margin0.3%+10.1 pt vs Q3 2020
Net margin-25.1%−17.6 pt vs Q3 2020
ended Feb 28, 2021 · filed Apr 8, 2021 · 39 d after period end